Genetic medicines that induce angiogenesis represent a promising strategy for the treatment of ischemic diseases. Many types of nonviral delivery systems have been tested as therapeutic angiogenesis agents. However, their delivery efficiency, and consequently therapeutic efficacy, remains to be further improved, as few of these technologies are being used in clinical applications. This article reviews the diverse nonviral gene delivery approaches that have been applied to the field of therapeutic angiogenesis, including plasmids, cationic polymers/lipids, scaffolds, and stem cells. This article also reviews clinical trials employing nonviral gene therapy and discusses the limitations of current technologies. Finally, this article proposes a future strategy to efficiently develop delivery vehicles that might be feasible for clinically relevant nonviral gene therapy, such as high-throughput screening of combinatorial libraries of biomaterials.
Bibliographical noteFunding Information:
This work was supported by the Industrial Strategic Technology Development Program (10035159) funded by the Ministry of Knowledge Economy , the Future-based Technology Development Program (2010-0020409) through the National Research Foundation of Korea funded by the Ministry of Education, Science and Technology , and the Basic Science Research Program (2010–0022037) through the National Research Foundation of Korea funded by the Ministry of Education, Science and Technology, Republic of Korea.
All Science Journal Classification (ASJC) codes
- Pharmaceutical Science